Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir : A cross-sectional study of the National Covid Cohort Collaborative (N3C)
© 2023 Pharmacotherapy Publications, Inc..
STUDY OBJECTIVE: To estimate the prevalence of potential moderate to severe drug-drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and evaluate risk factors associated with potential DDIs.
DESIGN: Cross-sectional study.
DATA SOURCE: Electronic health records from the National COVID Cohort Collaborative Enclave, one of the largest COVID-19 data resources in the United States.
PATIENTS: Outpatients aged ≥18 years and started nirmatrelvir/ritonavir between December 23, 2021 and March 31, 2022.
INTERVENTION: Nirmatrelvir/ritonavir.
MEASUREMENTS: The outcome is potential moderate to severe DDIs, defined as starting interacting medications reported by National Institutes of Health 30 days before or 10 days after starting nirmatrelvir/ritonavir.
MAIN RESULTS: Of 3214 outpatients who started nirmatrelvir/ritonavir, the mean age was 56.8 ± 17.1 years, 39.5% were male, and 65.8% were non-Hispanic white. Overall, 521 (16.2%) were potentially exposed to at least one moderate to severe DDI, most commonly to atorvastatin (19.2% of all DDIs), hydrocodone (14.0%), or oxycodone (14.0%). After adjustment for covariates, potential DDIs were more likely among individuals who were older (odds ratio [OR] 1.16 per 10-year increase, 95% confidence interval [CI] 1.08-1.25), male (OR 1.36, CI 1.09-1.71), smokers (OR 1.38, CI 1.10-1.73), on more co-medications (OR 1.35, CI 1.31-1.39), and with a history of solid organ transplant (OR 3.63, CI 2.05-6.45).
CONCLUSIONS: One in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 43(2023), 12 vom: 15. Dez., Seite 1251-1261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiao, Xuya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7R9A5P7H32 |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 18.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/phar.2860 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360391982 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360391982 | ||
| 003 | DE-627 | ||
| 005 | 20240218231850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/phar.2860 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM360391982 | ||
| 035 | |a (NLM)37539477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiao, Xuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir |b A cross-sectional study of the National Covid Cohort Collaborative (N3C) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 18.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Pharmacotherapy Publications, Inc. | ||
| 520 | |a STUDY OBJECTIVE: To estimate the prevalence of potential moderate to severe drug-drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and evaluate risk factors associated with potential DDIs | ||
| 520 | |a DESIGN: Cross-sectional study | ||
| 520 | |a DATA SOURCE: Electronic health records from the National COVID Cohort Collaborative Enclave, one of the largest COVID-19 data resources in the United States | ||
| 520 | |a PATIENTS: Outpatients aged ≥18 years and started nirmatrelvir/ritonavir between December 23, 2021 and March 31, 2022 | ||
| 520 | |a INTERVENTION: Nirmatrelvir/ritonavir | ||
| 520 | |a MEASUREMENTS: The outcome is potential moderate to severe DDIs, defined as starting interacting medications reported by National Institutes of Health 30 days before or 10 days after starting nirmatrelvir/ritonavir | ||
| 520 | |a MAIN RESULTS: Of 3214 outpatients who started nirmatrelvir/ritonavir, the mean age was 56.8 ± 17.1 years, 39.5% were male, and 65.8% were non-Hispanic white. Overall, 521 (16.2%) were potentially exposed to at least one moderate to severe DDI, most commonly to atorvastatin (19.2% of all DDIs), hydrocodone (14.0%), or oxycodone (14.0%). After adjustment for covariates, potential DDIs were more likely among individuals who were older (odds ratio [OR] 1.16 per 10-year increase, 95% confidence interval [CI] 1.08-1.25), male (OR 1.36, CI 1.09-1.71), smokers (OR 1.38, CI 1.10-1.73), on more co-medications (OR 1.35, CI 1.31-1.39), and with a history of solid organ transplant (OR 3.63, CI 2.05-6.45) | ||
| 520 | |a CONCLUSIONS: One in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a drug safety | |
| 650 | 4 | |a nirmatrelvir/ritonavir | |
| 650 | 4 | |a patient safety | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Mehta, Hemalkumar B |e verfasserin |4 aut | |
| 700 | 1 | |a Curran, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Garibaldi, Brian T |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, G Caleb |e verfasserin |4 aut | |
| 700 | 0 | |a National Covid Cohort Collaborative (N3C) Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Wilcox, Adam B |e investigator |4 oth | |
| 700 | 1 | |a Lee, Adam M |e investigator |4 oth | |
| 700 | 1 | |a Graves, Alexis |e investigator |4 oth | |
| 700 | 1 | |a Anzalone, Alfred Jerrod |e investigator |4 oth | |
| 700 | 1 | |a Manna, Amin |e investigator |4 oth | |
| 700 | 1 | |a Saha, Amit |e investigator |4 oth | |
| 700 | 1 | |a Olex, Amy |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Williams, Andrew E |e investigator |4 oth | |
| 700 | 1 | |a Southerland, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Girvin, Andrew T |e investigator |4 oth | |
| 700 | 1 | |a Walden, Anita |e investigator |4 oth | |
| 700 | 1 | |a Sharathkumar, Anjali A |e investigator |4 oth | |
| 700 | 1 | |a Amor, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Bates, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Hendricks, Brian |e investigator |4 oth | |
| 700 | 1 | |a Patel, Brijesh |e investigator |4 oth | |
| 700 | 1 | |a Bramante, Carolyn |e investigator |4 oth | |
| 700 | 1 | |a Ward-Caviness, Cavin |e investigator |4 oth | |
| 700 | 1 | |a Madlock-Brown, Charisse |e investigator |4 oth | |
| 700 | 1 | |a Suver, Christine |e investigator |4 oth | |
| 700 | 1 | |a Chute, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Dillon, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Wu, Chunlei |e investigator |4 oth | |
| 700 | 1 | |a Schmitt, Clare |e investigator |4 oth | |
| 700 | 1 | |a Takemoto, Cliff |e investigator |4 oth | |
| 700 | 1 | |a Housman, Dan |e investigator |4 oth | |
| 700 | 1 | |a Gabriel, Davera |e investigator |4 oth | |
| 700 | 1 | |a Eichmann, David A |e investigator |4 oth | |
| 700 | 1 | |a Mazzotti, Diego |e investigator |4 oth | |
| 700 | 1 | |a Brown, Don |e investigator |4 oth | |
| 700 | 1 | |a Boudreau, Eilis |e investigator |4 oth | |
| 700 | 1 | |a Hill, Elaine |e investigator |4 oth | |
| 700 | 1 | |a Zampino, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Marti, Emily Carlson |e investigator |4 oth | |
| 700 | 1 | |a Pfaff, Emily R |e investigator |4 oth | |
| 700 | 1 | |a French, Evan |e investigator |4 oth | |
| 700 | 1 | |a Koraishy, Farrukh M |e investigator |4 oth | |
| 700 | 1 | |a Mariona, Federico |e investigator |4 oth | |
| 700 | 1 | |a Prior, Fred |e investigator |4 oth | |
| 700 | 1 | |a Sokos, George |e investigator |4 oth | |
| 700 | 1 | |a Martin, Greg |e investigator |4 oth | |
| 700 | 1 | |a Lehmann, Harold |e investigator |4 oth | |
| 700 | 1 | |a Spratt, Heidi |e investigator |4 oth | |
| 700 | 1 | |a Liu, Hongfang |e investigator |4 oth | |
| 700 | 1 | |a Sidky, Hythem |e investigator |4 oth | |
| 700 | 1 | |a Hayanga, J W Awori |e investigator |4 oth | |
| 700 | 1 | |a Pincavitch, Jami |e investigator |4 oth | |
| 700 | 1 | |a Clark, Jaylyn |e investigator |4 oth | |
| 700 | 1 | |a Harper, Jeremy Richard |e investigator |4 oth | |
| 700 | 1 | |a Islam, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Ge, Jin |e investigator |4 oth | |
| 700 | 1 | |a Gagnier, Joel |e investigator |4 oth | |
| 700 | 1 | |a Saltz, Joel H |e investigator |4 oth | |
| 700 | 1 | |a Saltz, Joel |e investigator |4 oth | |
| 700 | 1 | |a Loomba, Johanna |e investigator |4 oth | |
| 700 | 1 | |a Buse, John |e investigator |4 oth | |
| 700 | 1 | |a Mathew, Jomol |e investigator |4 oth | |
| 700 | 1 | |a Rutter, Joni L |e investigator |4 oth | |
| 700 | 1 | |a McMurry, Julie A |e investigator |4 oth | |
| 700 | 1 | |a Guinney, Justin |e investigator |4 oth | |
| 700 | 1 | |a Starren, Justin |e investigator |4 oth | |
| 700 | 1 | |a Crowley, Karen |e investigator |4 oth | |
| 700 | 1 | |a Bradwell, Katie Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Walters, Kellie M |e investigator |4 oth | |
| 700 | 1 | |a Wilkins, Ken |e investigator |4 oth | |
| 700 | 1 | |a Gersing, Kenneth R |e investigator |4 oth | |
| 700 | 1 | |a Cato, Kenrick Dwain |e investigator |4 oth | |
| 700 | 1 | |a Murray, Kimberly |e investigator |4 oth | |
| 700 | 1 | |a Kostka, Kristin |e investigator |4 oth | |
| 700 | 1 | |a Northington, Lavance |e investigator |4 oth | |
| 700 | 1 | |a Pyles, Lee Allan |e investigator |4 oth | |
| 700 | 1 | |a Misquitta, Leonie |e investigator |4 oth | |
| 700 | 1 | |a Cottrell, Lesley |e investigator |4 oth | |
| 700 | 1 | |a Portilla, Lili |e investigator |4 oth | |
| 700 | 1 | |a Deacy, Mariam |e investigator |4 oth | |
| 700 | 1 | |a Bissell, Mark M |e investigator |4 oth | |
| 700 | 1 | |a Clark, Marshall |e investigator |4 oth | |
| 700 | 1 | |a Emmett, Mary |e investigator |4 oth | |
| 700 | 1 | |a Saltz, Mary Morrison |e investigator |4 oth | |
| 700 | 1 | |a Palchuk, Matvey B |e investigator |4 oth | |
| 700 | 1 | |a Haendel, Melissa A |e investigator |4 oth | |
| 700 | 1 | |a Adams, Meredith |e investigator |4 oth | |
| 700 | 1 | |a Temple-O'Connor, Meredith |e investigator |4 oth | |
| 700 | 1 | |a Kurilla, Michael G |e investigator |4 oth | |
| 700 | 1 | |a Morris, Michele |e investigator |4 oth | |
| 700 | 1 | |a Qureshi, Nabeel |e investigator |4 oth | |
| 700 | 1 | |a Safdar, Nasia |e investigator |4 oth | |
| 700 | 1 | |a Garbarini, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Sharafeldin, Noha |e investigator |4 oth | |
| 700 | 1 | |a Sadan, Ofer |e investigator |4 oth | |
| 700 | 1 | |a Francis, Patricia A |e investigator |4 oth | |
| 700 | 1 | |a Burgoon, Penny Wung |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Peter |e investigator |4 oth | |
| 700 | 1 | |a Payne, Philip R O |e investigator |4 oth | |
| 700 | 1 | |a Fuentes, Rafael |e investigator |4 oth | |
| 700 | 1 | |a Jawa, Randeep |e investigator |4 oth | |
| 700 | 1 | |a Erwin-Cohen, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Patel, Rena |e investigator |4 oth | |
| 700 | 1 | |a Moffitt, Richard A |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 43(2023), 12 vom: 15. Dez., Seite 1251-1261 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:1251-1261 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/phar.2860 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 12 |b 15 |c 12 |h 1251-1261 | ||